Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Raymond Dwek Biography and Net Worth

Director of United Therapeutics

Prof. Raymond A. Dwek CBE serves as Independent Director of the Company. Professor Dwek is a Fellow of the Royal Society, London, and has served as Director of the Glycobiology Institute at the University of Oxford since 1988. He also served as Professor of Glycobiology at the University of Oxford from 1988 through 2009, and currently serves as Professor Emeritus. He was President of the Institute of Biology (a professional organization) from 2008 through 2010. From 2000 to 2006, Professor Dwek served as head of the Department of Biochemistry at the University of Oxford. Professor Dwek has been serving in various positions at the University of Oxford since 1966. In 1988, Professor Dwek was the scientific founder of Oxford GlycoSciences PLC, which was publicly traded on the London Stock Exchange and Nasdaq, and he served as a member of its Board of Directors until its sale in 2003. He was the 2007 Kluge Chair of Technology and Society at the U.S. Library of Congress. Professor Dwek is the founder of glycobiology, the study of the structure, biosynthesis and biology of sugar chains attached to proteins. He has served as a United Therapeutics director since 2002.

What is Raymond A. Dwek's net worth?: The estimated net worth of Raymond A. Dwek is at least $629,265.00 as of August 2nd, 2024. Mr. Dwek owns 1,750 shares of United Therapeutics stock worth more than $629,265 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Dwek may own. Learn More about Raymond A. Dwek's net worth.
How do I contact Raymond A. Dwek?: The corporate mailing address for Mr. Dwek and other United Therapeutics executives is 1040 SPRING ST, SILVER SPRING MD, 20910. United Therapeutics can also be reached via phone at (301) 608-9292 and via email at [email protected]. Learn More on Raymond A. Dwek's contact information.
Has Raymond A. Dwek been buying or selling shares of United Therapeutics?: Raymond A. Dwek has not been actively trading shares of United Therapeutics over the course of the past ninety days. Most recently, Raymond Dwek sold 5,000 shares of the business's stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $325.35, for a transaction totalling $1,626,750.00. Following the completion of the sale, the director now directly owns 1,750 shares of the company's stock, valued at $569,362.50. Learn More on Raymond A. Dwek's trading history.
Who are United Therapeutics' active insiders?: United Therapeutics' insider roster includes Michael Benkowitz (COO), Christopher Causey (Director), Raymond Dwek (Director), James Edgemond (CFO), Paul Mahon (EVP), Nilda Mesa (Director), Judy Olian (Director), Christopher Patusky (Director), Martine Rothblatt (CEO), and Louis Sullivan (Director). Learn More on United Therapeutics' active insiders.
Are insiders buying or selling shares of United Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 80 times. They sold a total of 472,479 shares worth more than $143,828,624.02. The most recent insider tranaction occured on December, 18th when Director Louis W Sullivan sold 26,209 shares worth more than $9,781,722.98. Insiders at United Therapeutics own 11.9% of the company. Learn More about insider trades at United Therapeutics.
Information on this page was last updated on 12/18/2024.

Raymond A. Dwek Insider Trading History at United Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/2/2024	Sell	5,000	$325.35	$1,626,750.00	1,750
7/11/2022	Sell	2,160	$241.29	$521,186.40
6/29/2020	Sell	4,600	$116.81	$537,326.00	4,600
6/27/2019	Sell	3,750	$76.11	$285,412.50	3,750
6/29/2018	Sell	3,240	$113.07	$366,346.80
6/23/2017	Sell	3,490	$131.71	$459,667.90
6/2/2016	Sell	3,000	$118.82	$356,460.00	3,000
5/12/2016	Sell	3,000	$110.00	$330,000.00	3,000
2/4/2016	Sell	3,000	$122.66	$367,980.00
1/7/2016	Sell	3,000	$143.75	$431,250.00
12/3/2015	Sell	3,000	$157.22	$471,660.00
11/5/2015	Sell	3,000	$149.63	$448,890.00
10/1/2015	Sell	3,000	$131.32	$393,960.00
9/3/2015	Sell	3,000	$155.54	$466,620.00
7/2/2015	Sell	3,000	$171.59	$514,770.00
6/4/2015	Sell	3,000	$181.36	$544,080.00
5/1/2015	Sell	3,000	$159.58	$478,740.00
4/2/2015	Sell	3,000	$175.49	$526,470.00
3/5/2015	Sell	3,000	$157.59	$472,770.00
2/5/2015	Sell	3,000	$140.41	$421,230.00
12/4/2014	Sell	3,000	$131.58	$394,740.00
9/4/2014	Sell	3,000	$113.40	$340,200.00
8/1/2014	Sell	3,000	$89.52	$268,560.00
2/6/2014	Sell	3,000	$97.33	$291,990.00
1/2/2014	Sell	3,000	$111.41	$334,230.00
12/5/2013	Sell	3,000	$90.13	$270,390.00
11/1/2013	Sell	3,000	$89.18	$267,540.00
8/1/2013	Sell	3,000	$75.94	$227,820.00
6/6/2013	Sell	3,000	$63.77	$191,310.00
5/2/2013	Sell	3,000	$66.75	$200,250.00
4/11/2013	Sell	9,000	$61.35	$552,150.00

Raymond A. Dwek Buying and Selling Activity at United Therapeutics

United Therapeutics Company Overview

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $359.58

$357.98

$363.90

50 Day Range

MA: $371.01

$348.65

$410.00

2 Week Range

Now: $359.58

$208.62

$417.82

Volume

1,009,218 shs

Average Volume

449,066 shs

Market Capitalization

$16.05 billion

P/E Ratio

15.79

Dividend Yield

N/A

Beta

0.54

First JFK… next Elon?

From Porter & Company | Ad